ARS Pharmaceuticals EBITDA Margin Growth & History (SPRY)
ARS Pharmaceuticals's ebitda margin was −211.30% for fiscal 2025.
View full ARS Pharmaceuticals company overviewARS Pharmaceuticals annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −211.30% | −207.93 pp |
| 2024 | 2024-12-31 | −3.37% | +224729.96 pp |
| 2023 | 2023-12-31 | −224,733.33% | −222058.79 pp |
| 2022 | 2022-12-31 | −2,674.54% | −2325.09 pp |
| 2021 | 2021-12-31 | −349.46% | — |
ARS Pharmaceuticals quarterly ebitda margin
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −181.38% | +119.79 pp |
| Q1 2026 | 2026-03-31 | −263.43% | +199.35 pp |
| Q4 2025 | 2025-12-31 | −146.15% | −200.60 pp |
| Q3 2025 | 2025-09-30 | −162.46% | +884.35 pp |
| Q2 2025 | 2025-06-30 | −301.17% | +2763.23 pp |
| Q1 2025 | 2025-03-31 | −462.77% | — |
| Q4 2024 | 2024-12-31 | 54.45% | — |
| Q3 2024 | 2024-09-30 | −1,046.81% | — |
| Q2 2024 | 2024-06-30 | −3,064.40% | +202765.60 pp |
| Q2 2023 | 2023-06-30 | −205,830.00% | — |
| Q1 2023 | 2023-03-31 | −93,465.00% | −92425.48 pp |
| Q3 2022 | 2022-09-30 | −3,504.23% | — |
| Q1 2022 | 2022-03-31 | −1,039.52% | — |
ARS Pharmaceuticals ebitda margin trends
Between the periods ended 2021-12-31 and 2025-12-31, ARS Pharmaceuticals's ebitda margin increased from −349.46% to −211.30%, a change of +138.15 percentage points. The latest reported quarter, Q2 2026, shows −181.38%.
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ARS Pharmaceuticals source filings ↗